Fig. 3From: A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysisMean values (±SE) of serum E2(a), FSH(b) and LH(c) and in patients treated with toremifene and tamoxifen at each follow-up. * p < 0.05. Abbreviation: TAM tamoxifen, TOR toremifene, E2 estradiol, FSH follicle stimulating hormone, LH luteinizing hormoneBack to article page